Seow et al. also confirmed in their study of immunotherapy for colorectal cancer that the use of anti-PD-1/PD-L1 antibody, which closes the blocking of the PD-1/PD-L1 pathway, attenuates the tumor feasibility of tumorigenic effects of stem cells. Here, CD274 is linked to colorectal cancer.